Journal articleEndocr Relat Cancer2012
Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors.
- Journal
- Endocr Relat Cancer
- Published
- 14 September 2012
- Citations
- 20
These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
abstract license unknown
Octreotide and everolimus have demonstrated efficacy in neuroendocrine tumors. Pasireotide is a somatostatin analog with binding affinity to a broader range of somatostatin receptor subtypes than octreotide. … Excerpt only: this text is the publisher’s. Read it in full at the source.
Trials 1
- Its registry lists this paper as resultsPasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors NCT00804336↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.